What is NDC 72603-255?

72603-255 is the product NDC for Everolimus, Everolimus 5 mg/1 tablet, listed with the FDA by NorthStar RxLLC. It has 1 package NDC, shown above in 10- and 11-digit form.

NorthStar RxLLC, NDC labeler code 72603. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Everolimus?

65 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Everolimus NDC 72603-255 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72603-255Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72603-0255Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72603-255-01	7260302550172603025501	30 TABLET in 1 BOTTLE (72603-255-01)Marketed from Oct 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Everolimus
Generic name (nonproprietary): everolimus
Active ingredients: Everolimus — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: NorthStar RxLLCNDC labeler code 72603
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214182
Marketing start: Oct 1, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 72603-255_10865ecf-d37f-4062-ec4e-b8c8a9c36897SPL ID 10865ecf-d37f-4062-ec4e-b8c8a9c36897SPL set ID 5cfca904-b75c-5a39-8cb9-b99bb421bcebRxCUI 845507, 845515, 998189, 1119400UNII 9HW64Q8G6GUPC 0372603257014, 0372603256017, 0372603255010, 0372603254013
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472603025501 followed by a unit qualifier and the quantity

Package 72603-0255-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 2, 2024.

Indications (excerpt from the label)

Everolimus tablets are kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer Ever…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72603-255

What is NDC 72603-255?: 72603-255 is the product NDC for Everolimus, Everolimus 5 mg/1 tablet, listed with the FDA by NorthStar RxLLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Everolimus.
What is the active ingredient?: Everolimus.
Who is the labeler?: NorthStar RxLLC, NDC labeler code 72603. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Everolimus?: 65 other product NDCs are listed under this name. See all Everolimus NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Everolimus NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Everolimus	Everolimus .25 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-003	72319-0003-0272319-0003-60
Everolimus	Everolimus .5 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-015	72319-0015-0272319-0015-60
Everolimus	Everolimus .75 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-016	72319-0016-0272319-0016-60
Everolimus	Everolimus 1 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-017	72319-0017-0272319-0017-60
everolimus	Everolimus 7.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-032	82293-0032-1082293-0032-2182293-0032-31
everolimus	Everolimus 2.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-030	82293-0030-1082293-0030-2182293-0030-31
everolimus	Everolimus 5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-031	82293-0031-1082293-0031-2182293-0031-31
everolimus	Everolimus 10 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-033	82293-0033-1082293-0033-2182293-0033-31
everolimus	Everolimus .75 mg/1	TabletOral	Aurobindo Pharma Limited	59651-933	59651-0933-60
everolimus	Everolimus .25 mg/1	TabletOral	Aurobindo Pharma Limited	59651-931	59651-0931-60

All 66 Everolimus NDCs

Other NDCs under ANDA 214182

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214182
Product	Strength	Form · route	Labeler	Product NDC
Everolimus	Everolimus 2.5 mg/1	TabletOral	Biocon Pharma Inc.	70377-010
Everolimus	Everolimus 5 mg/1	TabletOral	Biocon Pharma Inc.	70377-011
Everolimus	Everolimus 7.5 mg/1	TabletOral	Biocon Pharma Inc.	70377-012
Everolimus	Everolimus 10 mg/1	TabletOral	Biocon Pharma Inc.	70377-013
Everolimus	Everolimus 2.5 mg/1	TabletOral	NorthStar RxLLC	72603-254
Everolimus	Everolimus 7.5 mg/1	TabletOral	NorthStar RxLLC	72603-256
Everolimus	Everolimus 10 mg/1	TabletOral	NorthStar RxLLC	72603-257
Torpenzeverolimus	Everolimus 2.5 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0245-0822
Torpenzeverolimus	Everolimus 5 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0245-0823
Torpenzeverolimus	Everolimus 7.5 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0245-0824
Torpenzeverolimus	Everolimus 10 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0245-0825